Twist Bioscience Co. (NASDAQ:TWST) COO Sells $496,320.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 10,340 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00. Following the completion of the sale, the chief operating officer now directly owns 221,061 shares in the company, valued at $10,610,928. This trade represents a 4.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total value of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total value of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total value of $296,636.65.

Twist Bioscience Trading Down 5.3 %

Shares of Twist Bioscience stock opened at $36.89 on Friday. The business’s fifty day moving average price is $43.90 and its 200 day moving average price is $45.91. Twist Bioscience Co. has a twelve month low of $18.80 and a twelve month high of $60.90. The stock has a market capitalization of $2.16 billion, a P/E ratio of -9.66 and a beta of 1.78.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC increased its position in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience in the second quarter worth $43,000. Blue Trust Inc. raised its stake in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience during the 2nd quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on TWST shares. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Barclays cut their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Evercore ISI raised their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Robert W. Baird upped their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.